Hangzhou New Bios Biopharmaceutical

NewAnjin Biopharmaceutical is a clinical-stage biotechnology company based in Hangzhou, China, specializing in the development of personalized cancer immunotherapies. The company utilizes its proprietary iNeo artificial intelligence platform to identify patient-specific tumor neoantigens for the design of precision vaccines and cell therapies. Their pipeline includes personalized neoantigen peptide vaccines and mRNA-based therapies currently undergoing clinical evaluation for various advanced solid tumors. By integrating bioinformatics with immunology, NewAnjin aims to provide highly targeted treatment options that overcome the limitations of traditional non-specific cancer therapies.